Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1BRAF V600E Mutation 1

Interventions

venetoclax 21Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4Dexamethasone 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2Mycophenolic Acid 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia × Cobicistat × Clear all
NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡